Rein Therapeutics Postpones Annual Shareholder Meeting Due to Lack of Quorum Rein Therapeutics announced the adjournment of its annual stockholders' meeting to July 23, 2025, due to insufficient attendance. Stakeholders encouraged to vote.

Rein Therapeutics Postpones Annual Shareholder Meeting Due to Lack of Quorum #Rein_Therapeutics #LTI-03 #RNTX

Rein Therapeutics Initiates Phase 2 Trial for LTI-03 in IPF Patients Rein Therapeutics has begun dosing patients in its Phase 2 RENEW trial for LTI-03, a novel treatment for idiopathic pulmonary fibrosis, with results expected in 2026.

Rein Therapeutics Initiates Phase 2 Trial for LTI-03 in IPF Patients #United_States #Austin #Rein_Therapeutics #LTI-03 #IPF

Rein Therapeutics Showcases Cutting-Edge Research at ATS 2025 Conference Rein Therapeutics presents groundbreaking research on LTI-03, showcasing its potential for treating idiopathic pulmonary fibrosis at the ATS 2025 conference.

Rein Therapeutics Showcases Cutting-Edge Research at ATS 2025 Conference #USA #Austin #Rein_Therapeutics #LTI-03 #ATS_2025

Rein Therapeutics' Latest Financial Results and Future Prospects in Biopharmaceuticals Rein Therapeutics reports its first quarter 2025 financial results, updates on RENEW trial, and collaborations, signaling a dynamic future.

Rein Therapeutics' Latest Financial Results and Future Prospects in Biopharmaceuticals #USA #Austin #Rein_Therapeutics #LTI-03 #RNTX

Rein Therapeutics Launches Phase 2 Study of LTI-03 for Treating IPF Patients Rein Therapeutics begins its Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis (IPF), aiming to assess safety and efficacy for patients. 120 will be enrolled.

Rein Therapeutics Launches Phase 2 Study of LTI-03 for Treating IPF Patients #United_States #Austin #Rein_Therapeutics #LTI-03 #IPF

Revolutionizing IPF Treatment: Rein Therapeutics Teams Up with Qureight for Innovative Phase 2 Trial Rein Therapeutics and Qureight Ltd are collaborating to integrate deep-learning technology into the Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis, enhancing the study's data analysis.

Revolutionizing IPF Treatment: Rein Therapeutics Teams Up with Qureight for Innovative Phase 2 Trial #None #Austin #Rein_Therapeutics #Qureight #IPF_Treatment

Rein Therapeutics to Showcase Innovative Therapies at Life Sciences Conference 2025 Rein Therapeutics is set to present its groundbreaking therapies at the Citizens Life Sciences Conference 2025, aimed at addressing critical medical needs.

Rein Therapeutics to Showcase Innovative Therapies at Life Sciences Conference 2025 #USA #New_York #biopharmaceuticals #Rein_Therapeutics #RNTX

Rein Therapeutics to Present Groundbreaking Research at ATS 2025 Conference Rein Therapeutics, a biopharmaceutical leader, announces an accepted abstract for presentation on innovative therapies at the ATS 2025 Conference in San Francisco.

Rein Therapeutics to Present Groundbreaking Research at ATS 2025 Conference #United_States #San_Francisco #Rein_Therapeutics #LTI-03 #ATS_2025

Rein Therapeutics Secures Two Patents for Innovative LTI-03 Dry Powder Inhalation Treatment Rein Therapeutics has received two new patents for its LTI-03, a dry powder inhalation product aimed at treating respiratory diseases, enhancing treatment options.

Rein Therapeutics Secures Two Patents for Innovative LTI-03 Dry Powder Inhalation Treatment #United_States #Austin #Patent #Rein_Therapeutics #LTI-03

Rein Therapeutics Unveils Breakthrough Study on Caveolin-1 Peptide in Pulmonary Fibrosis Rein Therapeutics shares crucial findings from a new study on the potential of a Caveolin-1-related peptide in combating pulmonary fibrosis and its implications for treatment.

Rein Therapeutics Unveils Breakthrough Study on Caveolin-1 Peptide in Pulmonary Fibrosis #United_States #Austin #Rein_Therapeutics #IPF #Caveolin-1

Rein Therapeutics Unveils Promising Financial Results and Plans for Future Development Rein Therapeutics highlights their clinical advancements and financial results for 2024, focusing on their lead drug LTI-03 for treating pulmonary diseases.

Rein Therapeutics Unveils Promising Financial Results and Plans for Future Development #United_States #Austin #Rein_Therapeutics #LTI-03 #IPF

Rein Therapeutics: New Branding Marks a Focused Approach on Pulmonary Disease Therapies Rein Therapeutics unveils its rebranding from Aileron Therapeutics, emphasizing its commitment to therapies for orphan pulmonary diseases.

Rein Therapeutics: New Branding Marks a Focused Approach on Pulmonary Disease Therapies #United_States #Austin #Rein_Therapeutics #Aileron_Therapeutics #LTI-03